Investors' excitement about Viking Therapeutics reached a fever pitch on Feb. 27, 2024, when the company announced the results from a phase 2 clinical study evaluating VK2735 in patients with obesity.

Viking Therapeutics aims to participate in the billion-dollar obesity market. The company’s most advanced candidate is in a phase 3 trial. 10 stocks we like better than Viking Therapeutics › ...

There aren't many hotter stocks on the market right now than Viking Therapeutics (NASDAQ: VKTX). Shares of the biopharmaceutical company have skyrocketed around 340% so far this year. However, those ...

But, in recent times, one particular treatment area has seen explosive demand -- and this has created a massive revenue opportunity for companies serving it or developing potential products. So ...

Among the hottest investments these days are pharma and biotech companies that make weight loss drugs. Demand for these products surpasses supply, and analysts predict that sales growth for the new ...